A Randomized, Double-blind, Multicenter Phase III Study of XNW5004 Tablets in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma
Plain-language summary
This trial is testing XNW5004 tablets (an investigational oral drug) for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 3 trial, which means the treatment is being compared to the current standard of care to determine if it works better. Patients are randomly assigned to treatment groups, and neither patients nor doctors know which treatment is being given. This trial does not currently have sites in the United States. The trial is currently recruiting patients.
Who can join (key eligibility)
- Age 18 Days to 70 Days years
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
XNW5004 ; Chidamide placebo (DRUG): XNW5004 + Chidamide placebo | XNW5004 placebo; Chidamide (DRUG): XNW5004 placebo + Chidamide
XNW5004 ; Chidamide placebo, XNW5004 placebo; Chidamide
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details